2024
Atypical pneumonia testing in transplant recipients
Feller F, Trubin P, Malinis M, Vogel J, Merwede J, Peaper D, Azar M. Atypical pneumonia testing in transplant recipients. Transplant Infectious Disease 2024, 26: e14256. PMID: 38430482, DOI: 10.1111/tid.14256.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationTransplant recipientsPathogens of pneumoniaAtypical pneumoniaAugmented immunosuppressionAtypical pathogensTest positivity rateChimeric antigen receptor T cellsHematopoietic stem cell transplant recipientsDiagnosis of atypical pneumoniaPositive rateCases of mycoplasma infectionStem cell transplantationSolid organ transplantationRetrospective cohort studyMycoplasma infectionImmunocompromised patientsCell transplantationAnalysis of diagnostic testsDiagnostic yieldTransplant cohortPost-transplantationT cellsCohort studyRates of testingClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2022
An outbreak of SARS‐CoV‐2 on a transplant unit in the early vaccination era
Roberts SC, Palacios C, Grubaugh ND, Alpert T, Ott IM, Breban MI, Initiative Y, Martinello RA, Smith C, Davis MW, Mcmanus D, Tirmizi S, Topal JE, Azar MM, Malinis M. An outbreak of SARS‐CoV‐2 on a transplant unit in the early vaccination era. Transplant Infectious Disease 2022, 24: e13782. PMID: 34969164, DOI: 10.1111/tid.13782.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Infection prevention practicesSARS-CoV-2 outbreakTransplant unitCOVID-19-associated morbiditySolid organ transplant recipientsSARS-CoV-2 vaccinationPrevention practicesHospital day 18Potential index casesOrgan transplant recipientsInfection prevention behaviorsMonoclonal antibody therapyCOVID-19SARS-CoV-2 clustersHospital staff membersWhole-genome sequencingAsymptomatic patientsTransplant recipientsPositive patientsAtypical presentationImmunocompromised patientsAntibody therapyVaccination eraDisease progression
2020
Gomori Methenamine Silver Stain on Bronchoalveolar Lavage Fluid Is Poorly Sensitive for Diagnosis of Pneumocystis jiroveci Pneumonia in HIV-Negative Immunocompromised Patients and May Lead to Missed or Delayed Diagnoses
Azar MM, Slotkin R, Abi-Raad R, Liu Y, Grant MH, Malinis MF. Gomori Methenamine Silver Stain on Bronchoalveolar Lavage Fluid Is Poorly Sensitive for Diagnosis of Pneumocystis jiroveci Pneumonia in HIV-Negative Immunocompromised Patients and May Lead to Missed or Delayed Diagnoses. Archives Of Pathology & Laboratory Medicine 2020, 144: 1003-1010. PMID: 31904277, DOI: 10.5858/arpa.2019-0394-oa.Peer-Reviewed Original ResearchHIV-negative immunocompromised patientsBronchoalveolar lavage fluidDiagnosis of PJPHIV-positive patientsImmunocompromised patientsLavage fluidGomori methenamine silver stainingPneumocystis jiroveci pneumoniaHIV-positive casesHuman immunodeficiency virusGomori methenamine silver stainMethenamine silver stainingMethenamine silver stainJiroveci pneumoniaBAL fluidHistorical gold standardRetrospective reviewImmunodeficiency virusPatientsLow burdenDiagnosisGMS stainGold standardPJPPneumonia